NT comparison among CTCAE, mCRES, ASTCT, and FDA label
| . | Patients included in FDA label (N = 106)* . | All patients (N = 111)† . | ||
|---|---|---|---|---|
| CTCAE, n (%) . | CTCAE regrade, n (%) . | mCRES, n (%) . | ASTCT, n (%) . | |
| Grade 1/2 | 43 (40.6) | 34 (30.6) | 5 (4.5) | 5 (4.5) |
| Grade 3 | 19 (17.9) | 11 (9.9) | 6 (5.4) | 8 (7.2) |
| Grade 4 | 5 (4.5) | 8 (7.2) | 6 (5.4) | |
| Total | 62 (58.5) | 50 (45.0) | 19 (17.1) | 19 (17.1) |
| . | Patients included in FDA label (N = 106)* . | All patients (N = 111)† . | ||
|---|---|---|---|---|
| CTCAE, n (%) . | CTCAE regrade, n (%) . | mCRES, n (%) . | ASTCT, n (%) . | |
| Grade 1/2 | 43 (40.6) | 34 (30.6) | 5 (4.5) | 5 (4.5) |
| Grade 3 | 19 (17.9) | 11 (9.9) | 6 (5.4) | 8 (7.2) |
| Grade 4 | 5 (4.5) | 8 (7.2) | 6 (5.4) | |
| Total | 62 (58.5) | 50 (45.0) | 19 (17.1) | 19 (17.1) |